Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial

BACKGROUND: With no approved treatments in Japan for the prevention of hereditary angioedema (HAE) attacks, there is a significant unmet need for long‐term prophylactic therapies for Japanese patients with HAE. Berotralstat (BCX7353) is an oral, once‐daily, highly selective inhibitor of plasma kalli...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohsawa, Isao, Honda, Daisuke, Suzuki, Yusuke, Fukuda, Tomoo, Kohga, Keisuke, Morita, Eishin, Moriwaki, Shinichi, Ishikawa, Osamu, Sasaki, Yoshihiro, Tago, Masaki, Chittick, Greg, Cornpropst, Melanie, Murray, Sharon C., Dobo, Sylvia M., Nagy, Eniko, Van Dyke, Sharon, Reese, Lacy, Best, Jessica M., Iocca, Heather, Collis, Phil, Sheridan, William P., Hide, Michihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247297/
https://www.ncbi.nlm.nih.gov/pubmed/33247955
http://dx.doi.org/10.1111/all.14670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247297/
https://www.ncbi.nlm.nih.gov/pubmed/33247955
http://dx.doi.org/10.1111/all.14670

Ejemplares similares